• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新兴疫苗面临的挑战及针对 SARS-CoV-2 变异株的未来有前景的候选疫苗。

Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants.

机构信息

Department of Microbial Biotechnology, Panjab University, Chandigarh, India.

Department of Biotechnology, Graphic Era Deemed to be University, Dehradun, India.

出版信息

J Immunol Res. 2024 Jan 25;2024:9125398. doi: 10.1155/2024/9125398. eCollection 2024.

DOI:10.1155/2024/9125398
PMID:38304142
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10834093/
Abstract

Since the COVID-19 outbreak, the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) virus has evolved into variants with varied infectivity. Vaccines developed against COVID-19 infection have boosted immunity, but there is still uncertainty on how long the immunity from natural infection or vaccination will last. The present study attempts to outline the present level of information about the contagiousness and spread of SARS-CoV-2 variants of interest and variants of concern (VOCs). The keywords like COVID-19 vaccine types, VOCs, universal vaccines, bivalent, and other relevant terms were searched in NCBI, Science Direct, and WHO databases to review the published literature. The review provides an integrative discussion on the current state of knowledge on the type of vaccines developed against SARS-CoV-2, the safety and efficacy of COVID-19 vaccines concerning the VOCs, and prospects of novel universal, chimeric, and bivalent mRNA vaccines efficacy to fend off existing variants and other emerging coronaviruses. Genomic variation can be quite significant, as seen by the notable differences in impact, transmission rate, morbidity, and death during several human coronavirus outbreaks. Therefore, understanding the amount and characteristics of coronavirus genetic diversity in historical and contemporary strains can help researchers get an edge over upcoming variants.

摘要

自 COVID-19 爆发以来,严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)病毒已经进化出具有不同传染性的变体。针对 COVID-19 感染开发的疫苗增强了免疫力,但对于自然感染或接种疫苗产生的免疫力能持续多久仍存在不确定性。本研究试图概述有关 SARS-CoV-2 变体和关注变体(VOCs)的传染性和传播的现有信息水平。在 NCBI、Science Direct 和世界卫生组织数据库中搜索了 COVID-19 疫苗类型、VOCs、通用疫苗、二价等关键词,并查阅了已发表的文献。该综述综合讨论了针对 SARS-CoV-2 开发的疫苗类型、针对 VOCs 的 COVID-19 疫苗的安全性和有效性,以及新型通用、嵌合和二价 mRNA 疫苗预防现有变体和其他新兴冠状病毒的功效的前景。可以看到,在几次人类冠状病毒爆发中,基因组变异非常显著,其影响、传播率、发病率和死亡率都有明显差异。因此,了解历史和当代菌株中冠状病毒遗传多样性的程度和特征可以帮助研究人员在即将出现的变体方面占据优势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e396/10834093/38b60f207e3a/JIR2024-9125398.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e396/10834093/ba1a8911b340/JIR2024-9125398.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e396/10834093/f4cc46f5d1b7/JIR2024-9125398.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e396/10834093/38b60f207e3a/JIR2024-9125398.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e396/10834093/ba1a8911b340/JIR2024-9125398.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e396/10834093/f4cc46f5d1b7/JIR2024-9125398.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e396/10834093/38b60f207e3a/JIR2024-9125398.003.jpg

相似文献

1
Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants.新兴疫苗面临的挑战及针对 SARS-CoV-2 变异株的未来有前景的候选疫苗。
J Immunol Res. 2024 Jan 25;2024:9125398. doi: 10.1155/2024/9125398. eCollection 2024.
2
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.SARS-CoV-2 变体和 COVID-19 疫苗:当前的挑战与未来策略。
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
3
mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.mRNA 疫苗诱导的 T 细胞对 SARS-CoV-2 关切变异株的反应完全相同,但根据先前的感染状态,其持久性和归巢特性存在差异。
Elife. 2021 Oct 12;10:e72619. doi: 10.7554/eLife.72619.
4
The way of SARS-CoV-2 vaccine development: success and challenges.SARS-CoV-2 疫苗的研发之路:成功与挑战。
Signal Transduct Target Ther. 2021 Nov 9;6(1):387. doi: 10.1038/s41392-021-00796-w.
5
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19(Sars-Cov-2)的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
6
COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants.COVID-19 挑战:探索针对流行和新兴 SARS-CoV-2 变体的有效疫苗策略。
Curr Pharm Des. 2022;28(35):2901-2913. doi: 10.2174/1381612828666220701160116.
7
SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern.针对关注变种具有广泛保护作用的二价 SARS-CoV-2 mRNA 疫苗。
Front Immunol. 2023 May 24;14:1195299. doi: 10.3389/fimmu.2023.1195299. eCollection 2023.
8
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.一种基于三聚体 RBD 的马赛克型 COVID-19 疫苗候选物可诱导针对奥密克戎和其他 SARS-CoV-2 变体的强大中和作用。
Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633.
9
Covid-19 vaccines and variants of concern: A review.Covid-19 疫苗和关注变种:综述。
Rev Med Virol. 2022 Jul;32(4):e2313. doi: 10.1002/rmv.2313. Epub 2021 Nov 9.
10
Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants.新型 SARS-CoV-2 变异株的进化、传播模式和突变特征。
mBio. 2021 Aug 31;12(4):e0114021. doi: 10.1128/mBio.01140-21.

引用本文的文献

1
Identification, functional analysis, and clinical applications of defective viral genomes.缺陷病毒基因组的鉴定、功能分析及临床应用
Front Microbiol. 2025 Jul 17;16:1642520. doi: 10.3389/fmicb.2025.1642520. eCollection 2025.
2
Moloney Murine Leukemia Virus-like Nanoparticles Pseudo-Typed with SARS-CoV-2 RBD for Vaccination Against COVID-19.用严重急性呼吸综合征冠状病毒2受体结合域假型化的莫洛尼鼠白血病病毒样纳米颗粒用于预防2019冠状病毒病的疫苗接种。
Int J Mol Sci. 2025 Jul 4;26(13):6462. doi: 10.3390/ijms26136462.
3
Safety and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine as a booster against SARS-CoV-2: a phase II, open-label, randomized, double-blinded study.

本文引用的文献

1
BF.7: a new Omicron subvariant characterized by rapid transmission.BF.7:一种以快速传播为特征的新型奥密克戎亚变种。
Clin Microbiol Infect. 2024 Jan;30(1):137-141. doi: 10.1016/j.cmi.2023.09.018. Epub 2023 Oct 5.
2
The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.具有免疫逃逸特性的新冠病毒奥密克戎亚变体迅速崛起:XBB.1.5和BQ.1.1亚变体。
MedComm (2020). 2023 Mar 15;4(2):e239. doi: 10.1002/mco2.239. eCollection 2023 Apr.
3
Non-Hodgkin Lymphoma Developed Shortly after mRNA COVID-19 Vaccination: Report of a Case and Review of the Literature.
PIKA佐剂重组SARS-CoV-2刺突蛋白亚单位疫苗作为SARS-CoV-2加强针的安全性和免疫原性:一项II期、开放标签、随机、双盲研究。
Clin Exp Vaccine Res. 2024 Oct;13(4):329-337. doi: 10.7774/cevr.2024.13.4.329. Epub 2024 Oct 31.
4
Sputnik V-Induced Antibodies against SARS-CoV-2 Variants during the Dissemination of the Gamma Variant in Venezuela.在委内瑞拉伽马变异株传播期间,Sputnik V 诱导的针对 SARS-CoV-2 变异株的抗体。
Viruses. 2024 Sep 18;16(9):1480. doi: 10.3390/v16091480.
5
Immunogenicity and Protective Efficacy of a Single Intranasal Dose Vectored Vaccine Based on Sendai Virus (Moscow Strain) against SARS-CoV-2 Variant of Concern.基于仙台病毒(莫斯科株)的单剂量鼻内载体疫苗对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株的免疫原性和保护效力
Vaccines (Basel). 2024 Jul 16;12(7):783. doi: 10.3390/vaccines12070783.
mRNA COVID-19 疫苗接种后不久发生非霍奇金淋巴瘤:病例报告及文献复习。
Medicina (Kaunas). 2023 Jan 12;59(1):157. doi: 10.3390/medicina59010157.
4
Bivalent Covid-19 Vaccines - A Cautionary Tale.二价新冠疫苗——一个警示故事。
N Engl J Med. 2023 Feb 9;388(6):481-483. doi: 10.1056/NEJMp2215780. Epub 2023 Jan 11.
5
Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape.COVID-19 疫苗领域新兴的异源 mRNA 增强策略。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2153532. doi: 10.1080/21645515.2022.2153532. Epub 2023 Jan 11.
6
Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants.针对新冠病毒变异株的二价mRNA疫苗的研发
Vaccines (Basel). 2022 Oct 26;10(11):1807. doi: 10.3390/vaccines10111807.
7
Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies.全球 2020 年 1 月至 2022 年 4 月 SARS-CoV-2 血清流行率:基于人群的标准化研究的系统评价和荟萃分析。
PLoS Med. 2022 Nov 10;19(11):e1004107. doi: 10.1371/journal.pmed.1004107. eCollection 2022 Nov.
8
Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants.基于嵌合mRNA的新冠疫苗可诱导针对奥密克戎和德尔塔变异株的保护性免疫。
Mol Ther Nucleic Acids. 2022 Dec 13;30:465-476. doi: 10.1016/j.omtn.2022.10.021. Epub 2022 Nov 2.
9
The immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy individuals: A systematic review and meta-analysis.健康个体中针对 SARS-CoV-2 的灭活疫苗的免疫原性:系统评价和荟萃分析。
Transpl Immunol. 2022 Dec;75:101732. doi: 10.1016/j.trim.2022.101732. Epub 2022 Oct 31.
10
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses.未佐剂化鼻内刺突疫苗引发针对沙贝科病毒的保护性黏膜免疫。
Science. 2022 Nov 25;378(6622):eabo2523. doi: 10.1126/science.abo2523.